Navigation Links
Arpida Announces Full Year 2008 Financial Results
Date:2/25/2009

n-process R&D. In addition, the company restructuring which was announced in November 2008, has led to several adjustments in balance sheet values of assets and liabilities. More information can be found in the Notes to the Financial Statements in the 2008 Annual Report.

Statutory Accounts

Since inception, Arpida has chosen to capitalise research and development costs in its Statutory Accounts. In light of the announced company restructuring and the sharply reduced market capitalisation, this policy was reviewed. It was decided to write down 100% of the capitalised R&D expenses, resulting in an impairment charge in the Statutory Accounts. This does not impact the consolidated accounts, as R&D was never capitalised in these.

Outlook

After completion of the restructuring that was initiated at the end of 2008, the burn rate is expected to fall to around CHF 1 million on average per month from the second quarter of 2009 onwards. Cash and financial investments are expected to be around CHF 17 million at year-end 2009.

Pipeline Development

Intravenous iclaprim in cSSSI - setback in regulatory process

In 2008, regulatory filings for intravenous iclaprim in complicated skin and skin structure infections (cSSSI) were submitted in the USA, the European Union and in Canada.

On 20 November 2008, the Anti-infective Drugs Advisory Committee of the US Food and Drug Administration (FDA) voted 17 to 2 against the approval of intravenous iclaprim for use in the treatment of patients with cSSSI. In January 2009, Arpida received the FDA's Complete Response Letter. The FDA indicated in its letter that they could not approve the application for intravenous iclaprim in its current form and required additional clinical data to demonstrate efficacy in order to gain approval. Arpida has initiated a dialogue with external experts and the FDA to develo
'/>"/>

SOURCE Arpida Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
(Date:7/10/2014)... to the International Atomic Energy Agency (IAEA) the ... acquiring sufficient quantities of plutonium or highly enriched ... device. The IAEA also notes that most cases ... which can be challenging to detect with most ... appearing this week in the Journal of ...
(Date:7/10/2014)... extremely challenging because there are many genetic variants that ... Now investigators reporting in the July 3rd issue of ... describe a strategy that may help reveal how such ... environmental exposures to affect the development of the nervous ... predispose individuals to schizophrenia. , The work takes ...
(Date:7/10/2014)... for crude 3-D glasses, polarized glasses, and shutter ... devices, used to trick the brain into perceiving ... obsolete with the introduction of new holography technology ... doctoral students Yuval Yifat, Michal Eitan, and Zeev ... nanoantennas that could be used for security as ...
Breaking Biology Technology:Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2New strategy could uncover genes at the root of psychiatric illnesses 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... in the late 1970s with the first IPOs taking place in ... than 25 years old. , ,An interesting article in Genetic ... that most industry cycles run about 50 years until they mature. ... 50-year cycle. A new industry of significance usually produces an industrial ...
... In a long-planned departure from its traditional focus, high-end ... the U.S. Army for development of two different products. ... that it has secured $2.2 million in federal contracts ... with the Armys Research, Development and Engineering Command (CERDEC) ...
... Mike Strand has always kept his eye out ... Delta Technology and Cray Research, Strand took a stride forward ... company based out of his home dealing with barcode software. ... had expanded into a worldwide enterprise bringing in close to ...
Cached Biology Technology:Biotech industry reaches midpoint in 50-year maturation cycle 2Biotech industry reaches midpoint in 50-year maturation cycle 3Biotech industry reaches midpoint in 50-year maturation cycle 4Biotech industry reaches midpoint in 50-year maturation cycle 5SLE of Eau Claire lands $2.2 million in federal contracts 2SLE of Eau Claire lands $2.2 million in federal contracts 3Online Kiosks founder Mike Strand uses contest to screen new business plan 2Online Kiosks founder Mike Strand uses contest to screen new business plan 3
(Date:7/11/2014)... the Wildlife Conservation Society shows that no-take zones ... species such as lobster, conch, and fish recover ... reef areas. , The reporttitled "Review of the ... research literature from no-take areas around the world. ... a recognized expert in marine protected areas and ...
(Date:7/11/2014)... 11, 2014--Researchers at the Department of Energy,s Oak ... awards, presented by R&D Magazine in recognition of ... awards recognize the tremendous value of our National ... and development at the National Labs continues to ... pursue the scientific and technological innovations necessary to ...
(Date:7/11/2014)... South Wales, Australia when NASA,s Aqua satellite passed overhead ... 11 (12:35 p.m. local time/11:35 p.m. EDT on July ... (NSW), the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard captured ... smoke (light brown) from various fires. Actively burning areas, ... , The New South Wales, Australia Government website "NSW ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... leading provider of,embedded speech solutions today announced the ... AG, according to SVOX CEO Volker Jantzen.,SVOX has ... developed,over 25 years, including the SpeechAdvance(TM) speech recognition ... majority of the Professional,Speech Processing Group,s employees will ...
... MAYWOOD, Ill. -- Most people know that too much sodium ... suggests that people trying to lower their blood pressure should ... effect to sodium. Researchers found that the ratio of ... cardiovascular disease than sodium or potassium alone. "There ...
... officials from the U.S. National Science Foundation and the ... today marked the occasion of the research vessel JOIDES ... and transit to Honolulu, after a complete transformation to ... The JOIDES Resolution is the U.S. research ...
Cached Biology News:SVOX Acquires Speech Processing Unit of Siemens AG, Expands Into Speech Recognition and Speech Dialog 2Cutting salt isn't the only way to reduce blood pressure 2Ocean research officials hail completion of modernization for US scientific ocean drilling vessel 2
Human PLUNC Biotinylated Affinity Purified PAb...
Human RXR beta/NR2B2 MAb (Clone H7341) Keywords: RXRbeta, RXRbeta, Retinoid X Receptor beta...
... polyclonal to GRASP1 ( Abpromise ... Antigen: Synthetic peptide corresponding ... C terminal region of rat GRASP1, ... Entrez GeneID: ...
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
Biology Products: